SEC Filing Timeline
8-KNov 10, 2026
Material agreement · Items 1.01,7.01,9.01
DEFA14ANov 06, 2026
Additional proxy
DEFA14ANov 06, 2026
Additional proxy
10-QNov 04, 2026
Quarterly report
8-KNov 04, 2026
Earnings release · Items 2.02,9.01
8-KOct 15, 2026
Reg FD disclosure · Items 7.01,9.01
8-KOct 15, 2026
Material agreement · Items 1.01,7.01,8.01,9.01
8-KOct 06, 2026
Shareholder vote results · Items 5.07
8-KSep 23, 2026
Shareholder vote results · Items 5.07
8-KSep 08, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
DEFA14AAug 14, 2026
Additional proxy
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
DEFA14AJul 30, 2026
Additional proxy
DEF 14AJul 30, 2026
Proxy statement
Recent News (Finnhub)
Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase 3 ...
Ocugen Q3 Earnings Call Highlights
Ocugen, Inc. Q3 2026 Earnings Call Summary
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
Ocugen (OCGN) Q3 2026 Earnings Call Transcript